CASIF — CASI Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.06m
- $38.79m
- $20.71m
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary
Brief: CASI Pharmaceuticals Inc Daniel Lang To Step Down From His Role As Co’S Chief Financial Officer
Casi Pharmaceuticals Inc Expected To Post A Loss Of 61 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Expected To Post A Loss Of 61 Cents A Share: Earnings Preview
Brief: Casi Pharmaceuticals Signs Agreement To Acquire Equity Interests In Precision Autoimmune Therapeutics
Brief: CASI Pharmaceuticals Announces Clinical Hold Of CID-103
Casi Pharmaceuticals falls after FDA puts experimental antibody drug on hold
Brief: Casi Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $200 Million- SEC Filing
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended September 30: Earnings Summary
Casi Pharmaceuticals Inc Expected To Post A Loss Of 62 Cents A Share: Earnings Preview
Brief: CASI Pharmaceuticals Says Position Of President Of Co Was Removed
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended In June: Earnings Summary
Casi Pharmaceuticals Inc Expected To Post A Loss Of 63 Cents A Share: Earnings Preview
Brief: Casi Pharmaceuticals Announces $15 Million Private Placement Financing By Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture And Dr. Wei-Wu He
Brief: Casi Pharmaceuticals Announces Plan To Submit Ind Application For Cid-103, An Anti-Cd 38 Antibody In Antibody-Mediated Rejection, And Receipt Of A Non-Binding Proposal To Acquire Entire China Business Of The Company
U.S. STOCKS ON THE MOVE-MakeMyTrip, WaFd, Bolt Biotherapeutics